7
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Risk of Suicide After Cancer Diagnosis in England

      research-article
      , MSc, DPhil 1 , , , MB, BChir 2 , , MSCi 1 , , BSc 1 , 3 , , MBChB, PhD, FRCS 4 , , MSc(Econ), MBBS, MRCPsych, PhD 5 , 6 , 7
      JAMA Psychiatry
      American Medical Association

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Key Points

          Question

          What is the risk of suicide after cancer diagnosis in England, and which subgroups of patients are most at risk?

          Findings

          In this population-based study of 4 722 099 adult patients with cancer, a 20% increased risk of suicide compared with the general population was noted, corresponding to 0.19 excess deaths per 10 000 person-years. Patients with mesothelioma, pancreatic, esophageal, and lung cancer had the highest risk.

          Meaning

          The first 6 months after diagnosis of cancer has been shown to be a critical period, identifying the time during which cancer care pathways should pay particular attention to the psychological health needs of the patients; as suicide is hard to predict, all patients should receive improved psychological support.

          Abstract

          Importance

          A diagnosis of cancer carries a substantial risk of psychological distress. There has not yet been a national population-based study in England of the risk of suicide after cancer diagnosis.

          Objectives

          To quantify suicide risk in patients with cancers in England and identify risk factors that may assist in needs-based psychological assessment.

          Design, Setting, and Participants

          Population-based study using data from the National Cancer Registration and Analysis Service in England linked to death certification data of 4 722 099 individuals (22 million person-years at risk). Patients (aged 18-99 years) with cancer diagnosed from January 1, 1995, to December 31, 2015, with follow-up until August 31, 2017, were included.

          Exposures

          Diagnosis of malignant tumors, excluding nonmelanoma skin cancer.

          Main Outcomes and Measures

          All deaths in patients that received a verdict of suicide or an open verdict at the inquest. Standardized mortality ratios (SMRs) and absolute excess risks (AERs) were calculated.

          Results

          Of the 4 722 099 patients with cancer, 50.3% were men and 49.7% were women. A total of 3 509 392 patients in the cohort (74.3%) were aged 60 years or older when the diagnosis was made. A total of 2491 patients (1719 men and 772 women) with cancer died by suicide, representing 0.08% of all deaths during the follow-up period. The overall SMR for suicide was 1.20 (95% CI, 1.16-1.25) and the AER per 10 000 person-years was 0.19 (95% CI, 0.15-0.23). The risk was highest among patients with mesothelioma, with a 4.51-fold risk corresponding to 4.20 extra deaths per 10 000 person-years. This risk was followed by pancreatic (3.89-fold), esophageal (2.65-fold), lung (2.57-fold), and stomach (2.20-fold) cancer. Suicide risk was highest in the first 6 months following cancer diagnosis (SMR, 2.74; 95% CI, 2.52-2.98).

          Conclusions and Relevance

          Despite low absolute numbers, the elevated risk of suicide in patients with certain cancers is a concern, representing potentially preventable deaths. The increased risk in the first 6 months after diagnosis may indicate an unmet need for psychological support. The findings of this study suggest a need for improved psychological support for all patients with cancer, and attention to modifiable risk factors, such as pain, particularly in specific cancer groups.

          Abstract

          This population-based study examines the risk of suicide in patients in England after diagnosis of cancer, including cancer type and stage, time since diagnosis, and sociodemographic factors.

          Related collections

          Most cited references30

          • Record: found
          • Abstract: found
          • Article: not found

          Suicide prevention strategies revisited: 10-year systematic review

          Many countries are developing suicide prevention strategies for which up-to-date, high-quality evidence is required. We present updated evidence for the effectiveness of suicide prevention interventions since 2005.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies.

            Substantial uncertainty exists about prevalence of mood disorders in patients with cancer, including those in oncological, haematological, and palliative-care settings. We aimed to quantitatively summarise the prevalence of depression, anxiety, and adjustments disorders in these settings. We searched Medline, PsycINFO, Embase, and Web of Knowledge for studies that examined well-defined depression, anxiety, and adjustment disorder in adults with cancer in oncological, haematological, and palliative-care settings. We restricted studies to those using psychiatric interviews. Studies were reviewed in accordance with PRISMA guidelines and a proportion meta-analysis was done. We identified 24 studies with 4007 individuals across seven countries in palliative-care settings. Meta-analytical pooled prevalence of depression defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM) or International Classification of Diseases (ICD) criteria was 16·5% (95% CI 13·1-20·3), 14·3% (11·1-17·9) for DSM-defined major depression, and 9·6% (3·6-18·1) for DSM-defined minor depression. Prevalence of adjustment disorder alone was 15·4% (10·1-21·6) and of anxiety disorders 9·8% (6·8-13·2). Prevalence of all types of depression combined was of 24·6% (17·5-32·4), depression or adjustment disorder 24·7% (20·8-28·8), and all types of mood disorder 29·0% (10·1-52·9). We identified 70 studies with 10,071 individuals across 14 countries in oncological and haematological settings. Prevalence of depression by DSM or ICD criteria was 16·3% (13·4-19·5); for DSM-defined major depression it was 14·9% (12·2-17·7) and for DSM-defined minor depression 19·2% (9·1-31·9). Prevalence of adjustment disorder was 19·4% (14·5-24·8), anxiety 10·3% (5·1-17·0), and dysthymia 2·7% (1·7-4·0). Combination diagnoses were common; all types of depression occurred in 20·7% (12·9-29·8) of patients, depression or adjustment disorder in 31·6% (25·0-38·7), and any mood disorder in 38·2% (28·4-48·6). There were few consistent correlates of depression: there was no effect of age, sex, or clinical setting and inadequate data to examine cancer type and illness duration. Interview-defined depression and anxiety is less common in patients with cancer than previously thought, although some combination of mood disorders occurs in 30-40% of patients in hospital settings without a significant difference between palliative-care and non-palliative-care settings. Clinicians should remain vigilant for mood complications, not just depression. None. Copyright © 2011 Elsevier Ltd. All rights reserved.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Statistics in Medicine

                Bookmark

                Author and article information

                Journal
                JAMA Psychiatry
                JAMA Psychiatry
                JAMA Psychiatry
                JAMA Psychiatry
                American Medical Association
                2168-622X
                2168-6238
                21 November 2018
                January 2019
                21 November 2018
                : 76
                : 1
                : 51-60
                Affiliations
                [1 ]National Cancer Registration and Analysis Service, Public Health England, Wellington House, London, United Kingdom
                [2 ]Bury St Edmunds GP Specialty Training Programme, West Suffolk Hospital, Bury St Edmunds, United Kingdom
                [3 ]Transforming Cancer Services Team for London, Skipton House, London, United Kingdom
                [4 ]Department of Surgery, West Suffolk National Health Service Foundation, Bury St Edmunds, Suffolk, United Kingdom
                [5 ]UCL Division of Psychiatry, University College London, London, United Kingdom
                [6 ]Camden and Islington National Health Service Foundation Trust, St Pancras Hospital, London, United Kingdom
                [7 ]St George’s University Hospitals National Health Service Foundation Trust, London, United Kingdom
                Author notes
                Article Information
                Corresponding Author: Katherine E. Henson, MSc, DPhil, National Cancer Registration and Analysis Service, Public Health England, Wellington House, 133-155 Waterloo Rd, London SE1 8UG, United Kingdom ( katherine.henson@ 123456phe.gov.uk ).
                Accepted for Publication: July 30, 2018.
                Published Online: November 21, 2018. doi:10.1001/jamapsychiatry.2018.3181
                Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2018 Henson KE et al. JAMA Psychiatry.
                Author Contributions: Dr Brock and Mr Charnock contributed equally to the study. Dr Henson had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
                Concept and design: Henson, Brock, Will, Pitman.
                Acquisition, analysis, or interpretation of data: Henson, Brock, Charnock, Wickramasinghe, Will, Pitman.
                Drafting of the manuscript: Henson, Brock, Will, Pitman.
                Critical revision of the manuscript for important intellectual content: Henson, Brock, Charnock, Wickramasinghe, Will, Pitman.
                Statistical analysis: Henson, Charnock, Wickramasinghe.
                Conflict of Interest Disclosures: None reported.
                Funding/Support: Dr Pitman received salary support as a Macmillan consultant liaison psychiatrist from Macmillan Cancer Support until October 2017.
                Role of the Funder/Sponsor: Macmillan Cancer Support had no role in the preparation, review, or approval of the manuscript.
                Additional Contributions: Chloe Bright, PhD (National Cancer Registration and Analysis Service), provided quality assurance of the Stata code. Data for this study are based on patient-level information collected by the National Health Service as part of the care and support of patients with cancers. The data are collated, maintained, and quality assured by the National Cancer Registration and Analysis Service, which is part of Public Health England.
                Article
                yoi180080
                10.1001/jamapsychiatry.2018.3181
                6583458
                30476945
                ddde6e19-abce-4191-b149-3f870fa282c9
                Copyright 2018 Henson KE et al. JAMA Psychiatry.

                This is an open access article distributed under the terms of the CC-BY License.

                History
                : 7 June 2018
                : 30 July 2018
                : 30 July 2018
                Categories
                Research
                Research
                Original Investigation
                Featured
                Online First

                Comments

                Comment on this article